Regenerative Bandage Using Fragment of Leminin
A Northwestern University team has developed a regenerative bandage that can promote the healing of diabetic ulcers 33% faster than one of the most popular bandages currently on the market. The scientists identified a segment of laminin (12 amino acids in length) called A5G81 that is critical for the wound-healing process. The protein, A5G81, is found in most of the body's tissues including the skin and it sends signals to cells, encouraging them to differentiate, migrate, and adhere to one another, creating a scaffold that facilitates the body's ability to regenerate tissue at the wound site. The regenerative bandage incorporates an antioxidant, anti-inflammatory hydrogel that is thermally responsive; it is a liquid when applied to the wound bed, then rapidly solidifies into a gel when exposed to body temperature. This phase change allows it to conform to the exact shape of the wound. The material can be rinsed off with cool saline, leaving the regenerating tissue undisturbed. By using a small fragment of laminin rather than the entire protein, it can be easily synthesized in the laboratory, making it more reproducible while keeping manufacturing costs low.
Nanoparticles for the Detection of Excessive Scarring
Excessive scarring can dramatically affect a patient's quality of life, both physically and psychologically, as the scars can impede movement and activity, and can be painful when stretched. Over 100 million patients in developed countries develop scarring problems annually, arising from 80 million elective and trauma surgery operations. Joint research from Nanyang Technological University in Singapore (NTU Singapore) and Northwestern University in the United States has shown (using animal and human skin samples) that new nanoparticles have the potential to quickly and accurately predict whether a wound is likely to lead to excessive scarring such as keloids and skin contractures. These nanoparticles (NanoFlares) with tiny DNA strands targeting particular genes are applied to closed wounds using a cream. After the nanoparticles have penetrated the skin cells for 24 hours, a handheld fluorescent microscope is used to look for signals, given out by the nanoparticles' interaction with target biomarkers inside the skin, that indicate abnormal scarring activity. NanoFlares could be a supplementary tool to monitor and analyse other skin diseases, such as skin cancer, because the DNA sequences on the nanoparticles are interchangeable.
Gel-based Dressing to Stop Bleeding
Researchers from the Department of Biomedical Engineering at Texas A&M University are developing an injectable hydrogel bandage combining a hydrogel base (a water-swollen polymer) and nanoparticles that interact with the body's natural blood-clotting mechanism. The hydrogel expands to stop bleeding by sealing the injured area while the surface of the nanoparticles attracts blood platelets that facilitate the natural clotting cascade of the body. In addition to the rapid clotting mechanism of the hydrogel composite, the engineers use the electric charge of the nanoparticles to add vascular endothelial growth factor (VEGF) that efficiently adhere to the particles. They tested the hydrogel/nanoparticle/VEGF combination in a cell culture test that uses a petri dish with a layer of endothelial cells on the surface to create a solid skin-like sheet. The sheet is then scratched down the center creating a rip or hole in the sheet that resembles a wound. When the hydrogel-containing VEGF bound to the nanoparticles was added to the damaged endothelial cell wound, the cells were induced to grow back and fill-in the scratched region, essentially mimicking the healing of a wound.
AcidOxidizing Solution to Fight Infection
APR Applied Pharma Research sa (APR) announces the publication in Advances in Skin & Wound Care (April 2018) of the results of a clinical pilot study on the efficacy and tolerability of Nexodyn AcidOxidizing Solution (AOS). Nexodyn Antimicrobial Wound Care Solution is an active wound cleanser that is effective on the modulation of the inflammatory mediators while offering an excellent tissue safety profile combined with bioburden control. The cleanser is differentiated by its highly pure hypochlorous acid (HCIO) (> 95% of the free chlorine species), low pH, and high oxidation-reductions potential (ORP). The pilot study included 30 patients with critically colonized or locally infected chronic leg ulcers of any origin in Austria. AOS was applied on each leg ulcer at every dressing change for 35 days together with a nonadherent gauze and a multi-purpose absorbent dressing. By the end of the study period, treatment with AOS led to the full healing of 37% of the chronic wounds as well as to a significant decrease in wound size (P < .001).
Acelity Acquires Crawford Healthcare
Wound care company Acelity has agreed to acquire UK-based wound care and dermatology firm Crawford Healthcare. Crawford Healthcare produces wound dressing products, including the superabsorbent KerraMax Care range, KerraFoam, and KerraCel foam and antimicrobial gelling fiber AWD range.
Topical Nitric Oxide for Wound Care
EDX110 is a sustained-release nitric oxide (NO)-generating medical device that can be delivered as a dressing, liquid, gel or inhaled spray. NO is involved in many physiological processes including vasodilatation and angiogenesis, inflammation, and antimicrobial activity. Laboratory tests have shown EDX110 rapidly and safely kills bacteria, viruses, and fungi, including several deadly antibiotic-resistant infections, such as MRSA and E. coli. EDX110 was evaluated in a multi-center, prospective, observer-blinded, parallel group, randomized controlled trial involved 135 participants with 148 ulcers (EDX110 - 75; Control - 73). Participants randomized to EDX110 achieved a median percentage area reduction of 88.6% compared with 46.9% for the control group (P = .016) at 12 weeks, 30% of which were clinically infected at baseline. EDX110 also increased the number of completely healed ulcers by more than 50% (49% vs. 30%), nearly doubling the complete healing of infected ulcers (45% vs. 23%) and significantly reducing hospitalisations and serious adverse events related to the ulcer compared with standard-of-care at 12 weeks.